BACKGROUND: No research was found that compared quality of life (QOL) outcomes of prostate cancer patients receiving intensity-modulated radiation therapies with prostate cancer patients receiving radical prostatectomy. OBJECTIVES: To (a) describe differences in QOL before and after three types of treatment for prostate cancer: radical prostatectomy, intensity-modulated radiation therapy + seed implantation (permanent brachytherapy), or intensity-modulated radiation therapy + high dose rate radiotherapy (temporary brachytherapy); and (b) investigate demographic, physical, and psychosocial variables that impact QOL of men with prostate cancer. METHODS: Data were collected on three occasions: baseline (prior to treatment), 1 month, and 3 months after beginning treatment. Measures included biographic data, physiological, and psychological measures. Analysis of variance and hierarchical regression were used to examine patterns, describe differences, and identify predictors of QOL in the three treatment groups. QOL was conceptualized as a multidimensional construct that included physical, psychological, social, and functional well-being and prostate cancer concerns. RESULTS: Groups differed significantly in bowel and urinary symptom scores and prostate cancer concerns at baseline, and in urinary and depressive symptoms at 3 months. There were no significant group differences at 1 month. DISCUSSION: Significant differences were found in QOL as measured with the Functional Assessment of Cancer Treatment-Prostate after treatment with radical prostatectomy, intensity-modulated radiation therapy + seed implantation, or intensity-modulated radiation therapy + high dose rate radiotherapy. Findings may provide healthcare providers with knowledge about treatment sequelae for prostate cancer, enable healthcare providers to educate patients about QOL outcomes of treatment for prostate cancer, and enable patients to make more informed treatment decisions.
BACKGROUND: No research was found that compared quality of life (QOL) outcomes of prostate cancerpatients receiving intensity-modulated radiation therapies with prostate cancerpatients receiving radical prostatectomy. OBJECTIVES: To (a) describe differences in QOL before and after three types of treatment for prostate cancer: radical prostatectomy, intensity-modulated radiation therapy + seed implantation (permanent brachytherapy), or intensity-modulated radiation therapy + high dose rate radiotherapy (temporary brachytherapy); and (b) investigate demographic, physical, and psychosocial variables that impact QOL of men with prostate cancer. METHODS: Data were collected on three occasions: baseline (prior to treatment), 1 month, and 3 months after beginning treatment. Measures included biographic data, physiological, and psychological measures. Analysis of variance and hierarchical regression were used to examine patterns, describe differences, and identify predictors of QOL in the three treatment groups. QOL was conceptualized as a multidimensional construct that included physical, psychological, social, and functional well-being and prostate cancer concerns. RESULTS: Groups differed significantly in bowel and urinary symptom scores and prostate cancer concerns at baseline, and in urinary and depressive symptoms at 3 months. There were no significant group differences at 1 month. DISCUSSION: Significant differences were found in QOL as measured with the Functional Assessment of Cancer Treatment-Prostate after treatment with radical prostatectomy, intensity-modulated radiation therapy + seed implantation, or intensity-modulated radiation therapy + high dose rate radiotherapy. Findings may provide healthcare providers with knowledge about treatment sequelae for prostate cancer, enable healthcare providers to educate patients about QOL outcomes of treatment for prostate cancer, and enable patients to make more informed treatment decisions.
Authors: Amy J Hoffman; Alexander von Eye; Audrey G Gift; Barbara A Given; Charles W Given; Marilyn Rothert Journal: Cancer Nurs Date: 2011 May-Jun Impact factor: 2.592
Authors: Elise L Lev; Lucille Sanzero Eller; John Kolassa; Glen Gejerman; Joan Colella; Patricia Lane; Suzanne Scrofine; Michael Esposito; Vincent Lanteri; John Scheuch; Ravi Munver; Bernadette Galli; Richard A Watson; Ihor Sawczuk Journal: World J Urol Date: 2007-03 Impact factor: 4.226
Authors: George Rodrigues; Xiaomei Yao; D Andrew Loblaw; Michael Brundage; Joseph L Chin Journal: Can Urol Assoc J Date: 2013 May-Jun Impact factor: 1.862
Authors: Amy J Hoffman; Alexander von Eye; Audrey G Gift; Barbara A Given; Charles W Given; Marilyn Rothert Journal: Nurs Res Date: 2009 Jan-Feb Impact factor: 2.381
Authors: Elise L Lev; Lucille Sanzero Eller; Glen Gejerman; John Kolassa; Joan Colella; Janine Pezzino; Patricia Lane; Ravi Munver; Michael Esposito; John Sheuch; Vincent Lanteri; Ihor Sawczuk Journal: Support Care Cancer Date: 2008-08-22 Impact factor: 3.603
Authors: Addie C Wootten; Jo-Anne M Abbott; Katherine E Chisholm; David W Austin; Britt Klein; Marita P McCabe; Denny Meyer; Anthony J Costello; Declan G Murphy Journal: BMC Cancer Date: 2014-02-11 Impact factor: 4.430